TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
The purpose of this study is to:
Inclusion Criteria
Exclusion Criteria
clinicaltrials@alnylam.com1-877-ALNYLAM
clinicaltrials@alnylam.com1-877-256-9526
Shenzhen Shi, 518053, China
Martinique, 97261, France
Matsumoto-shi, 390-8621, Japan
Lørenskog, 1478, Norway